DreaMed Advisor Pro (endo.digital)
Save to shortlistLast reviewed Oct 31, 2026 against the sources listed on this page · How we review
At a glance
DreaMed Advisor Pro is an FDA-authorized diabetes decision-support system (De Novo DEN170043, 2018, plus subsequent 510(k) clearances) that analyzes insulin-pump, continuous-glucose-monitor and…
- FDA:
- 510(k) K232722 +2 more
- Epic:
- Not on record
- Named users:
- 1 named in public reports
- Published study:
- Not on record
Description
DreaMed Advisor Pro is an FDA-authorized diabetes decision-support system (De Novo DEN170043, 2018, plus subsequent 510(k) clearances) that analyzes insulin-pump, continuous-glucose-monitor and self-monitored glucose data to generate personalized insulin-dosing recommendations (basal rate, carbohydrate ratio and correction factor) for clinicians managing type 1 diabetes. Built on the MD-Logic algorithm, it aims to bring specialist-level insulin titration to more care settings. DreaMed now markets its platform as endo.digital.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is DreaMed Advisor Pro (endo.digital) FDA cleared?
- The public FDA database has 3 records that our team matched to DreaMed Advisor Pro (endo.digital). The most recent is 510(k) K232722 (endo.digital Platform), decided Oct 2023. Check that the cleared use matches how you plan to use it.FDA record K232722
- Which health systems use DreaMed Advisor Pro (endo.digital)?
- Linked public reports name one organization: Yale New Haven Health. "Who's using this" below lists them all, plus any the maker reports. Ask the vendor for a reference at an organization like yours.Yale New Haven Health (Business Wire)
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Not assessed
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
1 organizationOrganizations named in public announcements or by the developer. Inclusion is not an endorsement.
Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.
Get weekly updates for Endocrinology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
WebsiteFDA database records
- K232722 · 510(k) · Oct 2023endo.digital Platform
- K210561 · 510(k) · Sep 2021Advisor Pro Platform
- K201476 · 510(k) · Aug 2020DreaMed Advisor Pro
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (5)Show
Dated events on this listing's public record, newest first.
Developer
DreaMed Diabetes
DreaMed Diabetes Ltd.
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →